FDC Limited (BOM:531599)
384.60
-0.10 (-0.03%)
At close: Jun 16, 2026
FDC Limited Revenue
In the fiscal year ending March 31, 2026, FDC Limited had annual revenue of 21.71B INR with 2.98% growth. FDC Limited had revenue of 5.85B in the quarter ending March 31, 2026, with 18.89% growth.
Revenue
21.71B
Revenue Growth
+2.98%
P/S Ratio
2.88
Revenue / Employee
3.17M
Employees
6,857
Market Cap
62.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 21.71B | 628.13M | 2.98% |
| Mar 31, 2025 | 21.08B | 1.65B | 8.50% |
| Mar 31, 2024 | 19.43B | 1.59B | 8.92% |
| Mar 31, 2023 | 17.84B | 2.56B | 16.74% |
| Mar 31, 2022 | 15.28B | 1.95B | 14.61% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 82.80B |
| Viyash Scientific | 34.20B |
| Unichem Laboratories | 22.65B |
| Morepen Laboratories | 18.06B |
| Sanofi India | 17.74B |
| Procter & Gamble Health | 14.08B |
| CORONA Remedies | 14.03B |
| Gufic Biosciences | 9.44B |
FDC Limited News
- 19 days ago - FDC reports Rs 585 crore revenue in Q4 FY26 with 18.9% growth - Business Upturn
- 20 days ago - FDC reports 18.9% revenue growth in Q4 FY26, driven by strong export performance - Business Upturn
- 4 weeks ago - FDC Limited receives US FDA ANDA approval for Cefixime Oral Suspension — opens new revenue line in US antibiotic market - Business Upturn
- 3 months ago - FDC reconstitutes board committees and appoints Mohan Chandavarkar as chairman - Business Upturn
- 9 months ago - FDC receives ANDA approval from U.S. FDA for Pilocarpine Hydrochloride Ophthalmic Solution USP - Business Upturn
- 1 year ago - FDC shares drop over 3% as Q4 EBITDA falls 4.2% YoY to Rs 54 crore, net profit down 16.4% YoY - Business Upturn
- 1 year ago - FDC receives US FDA approval for Cefixime 400 mg tablets - Business Upturn
- 1 year ago - FDC shares surge 11%, leading gains in BSE Healthcare index - Business Upturn